◼ Archived
Business
🔮 holds ✗
Teva autoimmune antibody notches ph. 2 win in celiac disease
Teva's experimental antibody TEV-408 meets its primary goal in a mid-stage celiac disease trial.
2 trends tracked about this subject — the full history, oldest to newest below.
Teva's experimental antibody TEV-408 meets its primary goal in a mid-stage celiac disease trial.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.